These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 23917087)

  • 21. Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitis.
    Ulanova M; Duta F; Puttagunta L; Schreiber AD; Befus AD
    Expert Opin Ther Targets; 2005 Oct; 9(5):901-21. PubMed ID: 16185147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Orally bioavailable Syk inhibitors with activity in a rat PK/PD model.
    Thoma G; Veenstra S; Strang R; Blanz J; Vangrevelinghe E; Berghausen J; Lee CC; Zerwes HG
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4642-7. PubMed ID: 26320624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spleen tyrosine kinase inhibition attenuates airway hyperresponsiveness and pollution-induced enhanced airway response in a chronic mouse model of asthma.
    Penton PC; Wang X; Amatullah H; Cooper J; Godri K; North ML; Khanna N; Scott JA; Chow CW
    J Allergy Clin Immunol; 2013 Feb; 131(2):512-20.e1-10. PubMed ID: 22981792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation.
    Ferguson GD; Delgado M; Plantevin-Krenitsky V; Jensen-Pergakes K; Bates RJ; Torres S; Celeridad M; Brown H; Burnett K; Nadolny L; Tehrani L; Packard G; Pagarigan B; Haelewyn J; Nguyen T; Xu L; Tang Y; Hickman M; Baculi F; Pierce S; Miyazawa K; Jackson P; Chamberlain P; LeBrun L; Xie W; Bennett B; Blease K
    PLoS One; 2016; 11(1):e0145705. PubMed ID: 26756335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sesquiterpene dimmer (DSF-27) inhibits the release of neuroinflammatory mediators from microglia by targeting spleen tyrosine kinase (Syk) and Janus kinase 2 (Jak2): Two major non-receptor tyrosine signaling proteins involved in inflammatory events.
    Zeng KW; Wang S; Dong X; Jiang Y; Jin HW; Tu PF
    Toxicol Appl Pharmacol; 2014 Mar; 275(3):244-56. PubMed ID: 24486434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of spleen tyrosine kinase attenuates allergen-mediated airway constriction.
    Moy LY; Jia Y; Caniga M; Lieber G; Gil M; Fernandez X; Sirkowski E; Miller R; Alexander JP; Lee HH; Shin JD; Ellis JM; Chen H; Wilhelm A; Yu H; Vincent S; Chapman RW; Kelly N; Hickey E; Abraham WM; Northrup A; Miller T; Houshyar H; Crackower MA
    Am J Respir Cell Mol Biol; 2013 Dec; 49(6):1085-92. PubMed ID: 23889698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imidazotriazines: Spleen Tyrosine Kinase (Syk) Inhibitors Identified by Free-Energy Perturbation (FEP).
    Lovering F; Aevazelis C; Chang J; Dehnhardt C; Fitz L; Han S; Janz K; Lee J; Kaila N; McDonald J; Moore W; Moretto A; Papaioannou N; Richard D; Ryan MS; Wan ZK; Thorarensen A
    ChemMedChem; 2016 Jan; 11(2):217-33. PubMed ID: 26381330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-inflammatory actions of Syk inhibitors in macrophages involve non-specific inhibition of toll-like receptors-mediated JNK signaling pathway.
    Lin YC; Huang DY; Chu CL; Lin WW
    Mol Immunol; 2010 Apr; 47(7-8):1569-78. PubMed ID: 20138367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of dual ZAP70 and Syk kinases inhibitors by docking into a rare C-helix-out conformation of Syk.
    Zhao H; Caflisch A
    Bioorg Med Chem Lett; 2014 Mar; 24(6):1523-7. PubMed ID: 24569110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives.
    Tan SL; Liao C; Lucas MC; Stevenson C; DeMartino JA
    Pharmacol Ther; 2013 May; 138(2):294-309. PubMed ID: 23396081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of type-II inhibitors using kinase structures.
    Lovering F; McDonald J; Whitlock GA; Glossop PA; Phillips C; Bent A; Sabnis Y; Ryan M; Fitz L; Lee J; Chang JS; Han S; Kurumbail R; Thorarensen A
    Chem Biol Drug Des; 2012 Nov; 80(5):657-64. PubMed ID: 22759374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The ability of an ethanol extract of Cinnamomum cassia to inhibit Src and spleen tyrosine kinase activity contributes to its anti-inflammatory action.
    Yu T; Lee S; Yang WS; Jang HJ; Lee YJ; Kim TW; Kim SY; Lee J; Cho JY
    J Ethnopharmacol; 2012 Jan; 139(2):566-73. PubMed ID: 22155395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.
    Kelly PN; Romero DL; Yang Y; Shaffer AL; Chaudhary D; Robinson S; Miao W; Rui L; Westlin WF; Kapeller R; Staudt LM
    J Exp Med; 2015 Dec; 212(13):2189-201. PubMed ID: 26621451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
    Uckun FM; Qazi S
    Expert Rev Anticancer Ther; 2010 Sep; 10(9):1407-18. PubMed ID: 20836676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biophysical and mechanistic insights into novel allosteric inhibitor of spleen tyrosine kinase.
    Hall J; Aulabaugh A; Rajamohan F; Liu S; Kaila N; Wan ZK; Ryan M; Magyar R; Qiu X
    J Biol Chem; 2012 Mar; 287(10):7717-27. PubMed ID: 22219190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Syk inhibitors].
    Kimura Y; Chihara K; Takeuchi K; Sada K
    Nihon Rinsho; 2013 Jul; 71(7):1248-52. PubMed ID: 23961675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel Syk family kinase inhibitor: design, synthesis, and structure-activity relationship of 1,2,4-triazolo[4,3-c]pyrimidine and 1,2,4-triazolo[1,5-c]pyrimidine derivatives.
    Hirabayashi A; Mukaiyama H; Kobayashi H; Shiohara H; Nakayama S; Ozawa M; Miyazawa K; Misawa K; Ohnota H; Isaji M
    Bioorg Med Chem; 2008 Aug; 16(15):7347-57. PubMed ID: 18585046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kinetic assay for characterization of spleen tyrosine kinase activity and inhibition with recombinant kinase and crude cell lysates.
    Li M; Luraghi P; Amour A; Qian XD; Carter PS; Clark CJ; Deakin A; Denyer J; Hobbs CI; Surby M; Patel VK; Schaefer EM
    Anal Biochem; 2009 Jan; 384(1):56-67. PubMed ID: 18762159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Steady state kinetics of spleen tyrosine kinase investigated by a real time fluorescence assay.
    Papp E; Tse JK; Ho H; Wang S; Shaw D; Lee S; Barnett J; Swinney DC; Bradshaw JM
    Biochemistry; 2007 Dec; 46(51):15103-14. PubMed ID: 18052078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Syk kinase inhibitors in allergic diseases.
    Denyer J; Patel V
    Drug News Perspect; 2009 Apr; 22(3):146-50. PubMed ID: 19440557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.